What is Endogenex?
Endogenex is a pioneering MedTech enterprise focused on addressing the root causes of type 2 diabetes through innovative, non-thermal endoscopic procedures. By targeting the damaged duodenum—a key site of metabolic dysfunction—the company utilizes pulsed electric fields (PEF) to stimulate natural cell regeneration. This outpatient approach represents a paradigm shift from traditional symptom management, aiming to potentially halt or reverse disease progression. Positioned at the intersection of gastroenterology and metabolic health, Endogenex is redefining the therapeutic landscape for chronic conditions through advanced bio-electronic medicine.
How much funding has Endogenex raised?
Endogenex has raised a total of $190.3M across 4 funding rounds:
Series A
$34M
Series B
$18.3M
Series C
$88M
Series C
$50M
Series A (2023): $34M with participation from Longitude Capital
Series B (2023): $18.3M, investors not publicly disclosed
Series C (2024): $88M supported by Lumira Ventures and Hatteras Venture Partners
Series C (2026): $50M featuring Arboretum Ventures
Key Investors in Endogenex
Lumira Ventures
Lumira Ventures is Canada's largest life sciences venture capital firm, specializing in investments in healthcare innovators across various stages, from early-stage to revenue-generating biotech, biotherapeutics, and medical devices.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors, providing both capital and strategic support to visionary founders.
Arboretum Ventures
Arboretum Ventures is a Midwest-based healthcare venture capital firm with over 20 years of experience in investing in innovative healthcare solutions, focusing on early-stage startups in under-ventured markets.
What's next for Endogenex?
With the successful closure of this major strategic investment, Endogenex is poised to scale its clinical operations and expand its research initiatives. The focus will likely shift toward executing pivotal clinical trials and navigating regulatory pathways to bring its PEF-based therapy to a broader patient population. As the company transitions from development to potential commercialization, the strategic support from its investor syndicate will be instrumental in navigating the complexities of the global healthcare market. Future efforts will prioritize long-term efficacy studies and the optimization of its specialized catheter delivery systems to ensure scalability and clinical adoption.
See full Endogenex company page
